Erratum: Regarding “KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis” (American Journal of Kidney Diseases (2013) 62(3) (403–441) (S0272638613009037) (10.1053/j.ajkd.2013.06.002));KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis

American Journal of Kidney Diseases

Volumn 62, Issue 3, 2013, Pages 403-441

  Beck, Laurence ^a   Bomback, Andrew S ^b   Choi, Michael J ^c   Holzman, Larry B ^d   Langford, Carol ^e   Mariani, Laura H ^f   Somers, Michael J ^g   Trachtman, Howard ^h   Waldman, Meryl ⁱ  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LEVAMISOLE; LIVE VACCINE; METHOTREXATE; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RIBAVIRIN; RITUXIMAB; STEROID; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

ACUTE KIDNEY FAILURE; CONGENITAL NEPHROTIC SYNDROME; DATA EXTRACTION; DISEASE ASSOCIATION; DOSE RESPONSE; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEDICAL PRACTICE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEPHRITIS; NEPHROTIC SYNDROME; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PLASMAPHERESIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TONSILLECTOMY;

EID: 84883237470     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2017.01.008     Document Type: Erratum

References (206)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group KDIGO Clinical Practice Guideline for Glomerulonephritis Kidney Inter Suppl 2 2012 139 274
2. N. Teeninga, J.E. Kist-van Holthe, N. van Rijswijk Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome J Am Soc Nephrol 24 1 2013 149 159
3. A. Gulati, A. Sinha, V. Sreenivas, A. Math, P. Hari, A. Bagga Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial Clin J Am Soc Nephrol 6 1 2011 63 69
4. E.M. Ruth, M.J. Kemper, E.P. Leumann, G.F. Laube, T.J. Neuhaus Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome J Pediatr 147 2 2005 202 207
5. S. Kangovi, M. Edwards, S. Woloszynek Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis Pediatr Nephrol 27 5 2012 813 819
6. F.B. Waldo, M.R. Benfield, E.C. Kohaut Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome Pediatr Nephrol 6 6 1992 503 505
7. M. Haas, S.M. Meehan, T.G. Karrison, B.H. Spargo Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997 Am J Kidney Dis 30 5 1997 621 631
8. S.M. Korbet, R.M. Genchi, R.Z. Borok, M.M. Schwartz The racial prevalence of glomerular lesions in nephrotic adults Am J Kidney Dis 27 5 1996 647 651
9. D.A. Black, G. Rose, D.B. Brewer Controlled trial of prednisone in adult patients with the nephrotic syndrome Br Med J 3 5720 1970 421 426
10. C.H. Coggins Adult minimal change nephropathy: experience of the collaborative study of glomerular disease Trans Am Clin Climatol Assoc 97 1986 18 26
11. S.M. Korbet, M.M. Schwartz, E.J. Lewis Minimal-change glomerulopathy of adulthood Am J Nephrol 8 4 1988 291 297
12. S.K. Mak, C.D. Short, N.P. Mallick Long-term outcome of adult-onset minimal-change nephropathy Nephrol Dial Transplant 11 11 1996 2192 2201
13. M. Waldman, R.J. Crew, A. Valeri Adult minimal-change disease: clinical characteristics, treatment, and outcomes Clin J Am Soc Nephrol 2 3 2007 445 453
14. J.J. Huang, S.C. Hsu, F.F. Chen, J.M. Sung, C.C. Tseng, M.C. Wang Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis Am J Nephrol 21 1 2001 28 34
15. K.G. Saag, R. Koehnke, J.R. Caldwell Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events Am J Med 96 2 1994 115 123
16. S.C. Palmer, K. Nand, G.F. Strippoli Interventions for minimal change disease in adults with nephrotic syndrome Cochrane Database Syst Rev 1 2008 CD001537
17. E. Imbasciati, R. Gusmano, A. Edefonti Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome Br Med J 291 6505 1985 1305 1308
18. C. Ponticelli, A. Edefonti, L. Ghio Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial Nephrol Dial Transplant 8 12 1993 1326 1332
19. M.J. Choi, J.A. Eustace, L.F. Gimenez Mycophenolate mofetil treatment for primary glomerular diseases Kidney Int 61 3 2002 1098 1114
20. S. Fujinaga, Y. Ohtomo, D. Hirano Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center Clin Nephrol 72 4 2009 268 273
21. Y.P. Siu, M.K. Tong, K. Leung, T.H. Kwan, T.C. Au The use of enteric-coated mycophenolate sodium in the treatment of relapsing and steroid-dependent minimal change disease J Nephrol 21 1 2008 127 131
22. G. Zilleruelo, S.L. Hsia, M. Freundlich, H.M. Gorman, J. Strauss Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome J Pediatr 104 1 1984 61 64
23. S. Swaminathan, N. Leung, D.J. Lager Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study Clin J Am Soc Nephrol 1 3 2006 483 487
24. R.C. Wiggins The spectrum of podocytopathies: a unifying view of glomerular diseases Kidney int 71 12 2007 1205 1214
25. V.D. D'Agati, F.J. Kaskel, R.J. Falk Focal segmental glomerulosclerosis N Engl J Med 365 25 2011 2398 2411
26. L. Barisoni, H.W. Schnaper, J.B. Kopp A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases Clin J Am Soc Nephrol 2 3 2007 529 542
27. S. Santin, B. Tazon-Vega, I. Silva Clinical value of NPHS2 analysis in early- and adult-onset steroid-resistant nephrotic syndrome Clin J Am Soc Nephrol 6 2 2011 344 354
28. A.K. Buscher, M. Konrad, M. Nagel Mutations in podocyte genes are a rare cause of primary FSGS associated with ESRD in adult patients Clin Nephrol 78 1 2012 47 53
29. T.C. Jungraithmayr, K. Hofer, P. Cochat Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation J Am Soc Nephrol 22 3 2011 579 585
30. R.G. Ruf, A. Lichtenberger, S.M. Karle Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome J Am Soc Nephrol 15 3 2004 722 732
31. S. Weber, O. Gribouval, E.L. Esquivel NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence Kidney Int 66 2 2004 571 579
32. J.C. Jennette, R.J. Falk Adult minimal change glomerulopathy with acute renal failure Am J Kidney Dis 16 5 1990 432 437
33. M. Praga, M.A. Martinez, A. Andres Acute renal failure and tubular dysfunction associated with minimal change nephrotic syndrome Nephrol Dial Transplant 4 10 1989 914 916
34. S. Troyanov, C.A. Wall, J.A. Miller, J.W. Scholey, D.C. Cattran Focal and segmental glomerulosclerosis: definition and relevance of a partial remission J Am Soc Nephrol 16 4 2005 1061 1068
35. J.J. Rydel, S.M. Korbet, R.Z. Borok, M.M. Schwartz Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment Am J Kidney Dis 25 4 1995 534 542
36. D.S. Goumenos, G. Tsagalis, A.M. El Nahas Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study Nephron Clin Pract 104 2 2006 c75 c82
37. N. Duncan, A. Dhaygude, J. Owen Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy Nephrol Dial Transplant 19 12 2004 3062 3067
38. D.C. Cattran, G.B. Appel, L.A. Hebert A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis North America Nephrotic Syndrome Study Group Kidney Int 56 6 1999 2220 2226
39. N. Braun, F. Schmutzler, C. Lange Immunosuppressive treatment for focal segmental glomerulosclerosis in adults Cochrane Database Syst Rev 3 2008 CD003233
40. C. Ponticelli, G. Rizzoni, A. Edefonti A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome Kidney Int 43 6 1993 1377 1384
41. G.M. Ghiggeri, P. Catarsi, F. Scolari Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study Clin Ther 26 9 2004 1411 1418
42. M. Naesens, D.R. Kuypers, M. Sarwal Calcineurin inhibitor nephrotoxicity Clin J Am Soc Nephrol 4 2 2009 481 508
43. D.S. Gipson, H. Trachtman, F.J. Kaskel Clinical trial of focal segmental glomerulosclerosis in children and young adults Kidney Int 80 8 2011 868 878
44. 2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy Kidney Int 82 7 2012 797 804
45. H.C. Stanescu, M. Arcos-Burgos, A. Medlar Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy N Engl J Med 364 7 2011 616 626
46. C. Murtas, M. Bruschi, G. Candiano Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy Clin J Am Soc Nephrol 7 9 2012 1394 1400
47. R. Bjorneklett, B.E. Vikse, E. Svarstad Long-term risk of cancer in membranous nephropathy patients Am J Kidney Dis 50 3 2007 396 403
48. N. Polanco, E. Gutierrez, A. Covarsi Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy J Am Soc Nephrol 21 4 2010 697 704
49. L. Fritsche, K. Budde, L. Farber Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant 14 4 1999 1036 1038
50. E. Alexopoulos, A. Papagianni, M. Tsamelashvili, M. Leontsini, D. Memmos Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome Nephrol Dial Transplant 21 11 2006 3127 3132
51. R. Naumovic, D. Jovanovic, S. Pavlovic, M. Stosovic, J. Marinkovic, G. Basta-Jovanovic Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: a 3-year prospective study Biomed Pharmacother 65 2 2011 105 110
52. M. Praga, V. Barrio, G.F. Juarez, J. Luno Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial Kidney Int 71 9 2007 924 930
53. P. Ruggenenti, C. Chiurchiu, V. Brusegan Rituximab in idiopathic membranous nephropathy: a one-year prospective study J Am Soc Nephrol 14 7 2003 1851 1857
54. F.C. Fervenza, F.G. Cosio, S.B. Erickson Rituximab treatment of idiopathic membranous nephropathy Kidney Int 73 1 2008 117 125
55. F.C. Fervenza, R.S. Abraham, S.B. Erickson Rituximab therapy in idiopathic membranous nephropathy: a 2-year study Clin J Am Soc Nephrol 5 12 2010 2188 2198
56. P. Ruggenenti, P. Cravedi, A. Chianca Rituximab in idiopathic membranous nephropathy J Am Soc Nephrol 23 8 2012 1416 1425
57. B. Dussol, S. Morange, S. Burtey Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial Am J Kidney Dis 52 4 2008 699 705
58. T.M. Chan, A.W. Lin, S.C. Tang Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome Nephrology 12 6 2007 576 581
59. A.J. Branten, P.W. du Buf-Vereijken, M. Vervloet, J.F. Wetzels Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide Am J Kidney Dis 50 2 2007 248 256
60. L. Senthil Nayagam, A. Ganguli, M. Rathi Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study Nephrol Dial Transplant 23 6 2008 1926 1930
61. A.S. Bomback, J. Radhakrishnan Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) Discov Med 12 63 2011 91 96
62. M.M. Moxey-Mims, F.B. Stapleton, L.G. Feld Applying decision analysis to management of adolescent idiopathic nephrotic syndrome Pediatr Nephrol 8 6 1994 660 664
63. 2R-associated membranous nephropathy in adolescents and young adults [abstract] In: American Society of Nephrology Kidney Week. Vol 23. San Diego, CA JAm Soc Nephrol 2012 721A
64. 2R glomerular deposits in membranous nephropathy N Engl J Med 364 7 2011 689 690
65. R.P. Valentini, T.K. Mattoo, G. Kapur, A. Imam Membranous glomerulonephritis: treatment response and outcome in children Pediatr Nephrol 24 2 2009 301 308
66. S.J. Barbour, A. Greenwald, O. Djurdjev Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis Kidney Int 81 2 2012 190 195
67. S. Sethi, F.C. Fervenza, Y. Zhang C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up Kidney Int 82 4 2012 465 473
68. A. Servais, L.H. Noel, L.T. Roumenina Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies Kidney Int 82 4 2012 454 464
69. S. Sethi, C.M. Nester, R.J. Smith Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion Kidney Int 81 5 2012 434 441
70. S. Sethi, F.C. Fervenza Membranoproliferative glomerulonephritis - a new look at an old entity N Engl J Med 366 12 2012 1119 1131
71. F. Fakhouri, V. Fremeaux-Bacchi, L.H. Noel, H.T. Cook, M.C. Pickering C3 glomerulopathy: a new classification Nat Rev Nephrol 6 8 2010 494 499
72. S. Sethi, F.C. Fervenza Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification Semin Nephrol 31 4 2011 341 348
73. Y. Zhang, N.C. Meyer, K. Wang Causes of alternative pathway dysregulation in dense deposit disease Clin J Am Soc Nephrol 7 2 2012 265 274
74. P. Tarshish, J. Bernstein, J.N. Tobin, C.M. Edelmann Jr Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone - a report of the International Study of Kidney Disease in Children Pediatr Nephrol 6 2 1992 123 130
75. M.C. Braun, C.D. West, C.F. Strife Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen Am J Kidney Dis 34 6 1999 1022 1032
76. N. Bagheri, E. Nemati, K. Rahbar, A. Nobakht, B. Einollahi, S. Taheri Cyclosporine in the treatment of membranoproliferative glomerulonephritis Arch Iran Med 11 1 2008 26 29
77. H. Matsumoto, T. Shibasaki, I. Ohno [Effect of cyclosporin monotherapy on proteinuria in a patient with membranoproliferative glomerulonephritis] Nihon Jinzo Gakkai Shi 37 4 1995 258 262
78. M. Yuan, J. Zou, X. Zhang Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis Clin Nephrol 73 5 2010 354 359
79. S. De, D. Al-Nabhani, P. Thorner, D. Cattran, T.D. Piscione, C. Licht Remission of resistant MPGN type I with mycophenolate mofetil and steroids Pediatr Nephrol 24 3 2009 597 600
80. G. Jones, M. Juszczak, E. Kingdon, M. Harber, P. Sweny, A. Burns Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids Nephrol Dial Transplant 19 12 2004 3160 3164
81. R.J. Smith, J. Alexander, P.N. Barlow New approaches to the treatment of dense deposit disease J Am Soc Nephrol 18 9 2007 2447 2456
82. A.S. Bomback, R.J. Smith, G.R. Barile Eculizumab for dense deposit disease and C3 glomerulonephritis Clin J Am Soc Nephrol 7 5 2012 748 756
83. L.C. Herlitz, A.S. Bomback, G.S. Markowitz Pathology after eculizumab in dense deposit disease and C3 GN J Am Soc Nephrol 23 7 2012 1229 1237
84. S. Radhakrishnan, A. Lunn, M. Kirschfink Eculizumab and refractory membranoproliferative glomerulonephritis N Engl J Med 366 12 2012 1165 1166
85. S.H. Nasr, M.E. Fidler, A.M. Valeri Postinfectious glomerulonephritis in the elderly J Am Soc Nephrol 22 1 2011 187 195
86. J.I. Zeledon, R.L. McKelvey, K.S. Servilla Glomerulonephritis causing acute renal failure during the course of bacterial infections Histological varieties, potential pathogenetic pathways and treatment Int Urol Nephrol 40 2 2008 461 470
87. C.E. Gordon, E.M. Balk, B.N. Becker KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD Am J Kidney Dis 52 5 2008 811 825
88. D. Batisse, M. Karmochkine, C. Jacquot, M.D. Kazatchkine, L. Weiss Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa Eur J Gastroenterol Hepatol 16 7 2004 701 703
89. O. Lidove, P. Cacoub, P. Hausfater [Cryoglobulinemia and hepatitis C: worsening of peripheral neuropathy after interferon alpha treatment] Gastroenterol Clin Biol 23 3 1999 403 406
90. S. De Vita, L. Quartuccio, M. Isola A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis Arthritis Rheum 64 3 2012 843 853
91. M.C. Sneller, Z. Hu, C.A. Langford A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis Arthritis Rheum 64 3 2012 835 842
92. G.K. Lau, T. Piratvisuth, K.X. Luo Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 26 2005 2682 2695
93. P. Marcellin, G.K. Lau, F. Bonino Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 12 2004 1206 1217
94. C.M. Mastroianni, M. Lichtner, R. Citton Current trends in management of hepatitis B virus reactivation in the biologic therapy era World J Gastroenterol 14 34 2011 3881 3887 17
95. J.A. Eustace, E. Nuermberger, M. Choi, P.J. Scheel Jr, R. Moore, W.A. Briggs Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids Kidney Int 58 3 2000 1253 1260
96. M.S. Kumar, D.R. Sierka, A.M. Damask Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients Kidney Int 67 4 2005 1622 1629
97. P.G. Stock, B. Barin, B. Murphy Outcomes of kidney transplantation in HIV-infected recipients N Engl J Med 363 21 2010 2004 2014
98. A.G. Gharavi, K. Kiryluk, M. Choi Genome-wide association study identifies susceptibility loci for IgA nephropathy Nat Genet 43 4 2011 321 327
99. J. Novak, B.A. Julian, M. Tomana, J. Mestecky IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy Semin Nephrol 28 1 2008 78 87
100. H. Suzuki, R. Fan, Z. Zhang Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity J Clin Invest 119 6 2009 1668 1677
101. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification Kidney Int 76 5 2009 534 545
102. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults Kidney Int 77 10 2010 921 927
103. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility Kidney Int 76 5 2009 546 556
104. M.G. Radford Jr, J.V. Donadio Jr, E.J. Bergstralh, J.P. Grande Predicting renal outcome in IgA nephropathy J Am Soc Nephrol 8 2 1997 199 207
105. H.N. Reich, S. Troyanov, J.W. Scholey, D.C. Cattran Toronto Glomerulonephritis Registry Remission of proteinuria improves prognosis in IgA nephropathy J Am Soc Nephrol 18 12 2007 3177 3183
106. M. Praga, E. Gutierrez, E. Gonzalez, E. Morales, E. Hernandez Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial J Am Soc Nephrol 14 6 2003 1578 1583
107. P.K. Li, C.B. Leung, K.M. Chow Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study Am J Kidney Dis 47 5 2006 751 760
108. R. Coppo, L. Peruzzi, A. Amore IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria J Am Soc Nephrol 18 6 2007 1880 1888
109. National Institute of Health Workgroup The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents Pediatrics 114 2 2004 555 576 (suppl 4th Report)
110. C. Pozzi, S. Andrulli, L. Del Vecchio Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial J Am Soc Nephrol 15 1 2004 157 163
111. J. Lv, H. Zhang, Y. Chen Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial Am J Kidney Dis 53 1 2009 26 32
112. C. Manno, D.D. Torres, M. Rossini, F. Pesce, F.P. Schena Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy Nephrol Dial Transplant 24 12 2009 3694 3701
113. C. Pozzi, P.G. Bolasco, G.B. Fogazzi Corticosteroids in IgA nephropathy: a randomised controlled trial Lancet 353 9156 1999 883 887
114. J. Lv, D. Xu, V. Perkovic Corticosteroid therapy in IgA nephropathy J Am Soc Nephrol 23 6 2012 1108 1116
115. F.W. Ballardie, I.S. Roberts Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy J Am Soc Nephrol 13 1 2002 142 148
116. R.G. Walker, S.H. Yu, J.E. Owen, P. Kincaid-Smith The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial Clin Nephrol 34 3 1990 103 107
117. K.T. Woo, G.S. Lee The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin Clin Nephrol 35 4 1991 184
118. C. Pozzi, S. Andrulli, A. Pani Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy J Am Soc Nephrol 21 10 2010 1783 1790
119. N. Yoshikawa, M. Honda, K. Iijima Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial Clin J Am Soc Nephrol 1 3 2006 511 517
120. G. Frisch, J. Lin, J. Rosenstock Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial Nephrol Dial Transplant 20 10 2005 2139 2145
121. B.D. Maes, R. Oyen, K. Claes Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study Kidney Int 65 5 2004 1842 1849
122. S. Tang, J.C. Leung, L.Y. Chan Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy Kidney Int 68 2 2005 802 812
123. S.C. Tang, A.W. Tang, S.S. Wong, J.C. Leung, Y.W. Ho, K.N. Lai Long-term study of mycophenolate mofetil treatment in IgA nephropathy Kidney Int 77 6 2010 543 549
124. J.V. Donadio Jr, J.P. Grande, E.J. Bergstralh, R.A. Dart, T.S. Larson, D.C. Spencer The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial Mayo Nephrology Collaborative Group J Am Soc Nephrol 10 8 1999 1772 1777
125. P.M. Ferraro, G.F. Ferraccioli, G. Gambaro, P. Fulignati, S. Costanzi Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial Nephrol Dial Transplant 24 1 2009 156 160
126. W.M. Bennett, R.G. Walker, P. Kincaid-Smith Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial Clin Nephrol 31 3 1989 128 131
127. E.E. Pettersson, S. Rekola, L. Berglund Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study Clin Nephrol 41 4 1994 183 190
128. Y. Wang, J. Chen, Y. Wang, Y. Chen, L. Wang, Y. Lv A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy Nephrol Dial Transplant 26 6 2011 1923 1931
129. K.N. Lai, F.M. Lai, K.W. Chan, C.P. Ho, A.C. Leung, J. Vallance-Owen An overlapping syndrome of IgA nephropathy and lipoid nephrosis Am J Clin Pathol 86 6 1986 716 723
130. K.N. Lai, F.M. Lai, C.P. Ho, K.W. Chan Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial Clin Nephrol 26 4 1986 174 180
131. S.M. Kim, K.C. Moon, K.H. Oh Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome J Korean Med Sci 24 suppl 2009 S44 S49
132. S.N. Heyman, M. Brezis Acute renal failure in glomerular bleeding: a puzzling phenomenon Nephrol Dial Transplant 10 5 1995 591 593
133. E. Gutierrez, E. Gonzalez, E. Hernandez Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy Clin J Am Soc Nephrol 2 1 2007 51 57
134. J.A. Moreno, C. Martin-Cleary, E. Gutierrez AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences Clin J Am Soc Nephrol 7 1 2012 175 184
135. M. Praga, V. Gutierrez-Millet, J.J. Navas Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy Kidney Int 28 1 1985 69 74
136. Z. Tang, Y. Wu, Q.W. Wang Idiopathic IgA nephropathy with diffuse crescent formation Am J Nephrol 22 5-6 2002 480 486
137. T. Abe, H. Kida, M. Yoshimura Participation of extracapillary lesions (ECL) in progression of IgA nephropathy Clin Nephrol 25 1 1986 37 41
138. J.A. Tumlin, V. Lohavichan, R. Hennigar Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide Nephrol Dial Transplant 18 7 2003 1321 1329
139. O. Jauhola, J. Ronkainen, O. Koskimies Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset Pediatr Nephrol 27 6 2012 933 939
140. Y. Xia, J. Mao, Y. Chen Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb Pediatr Nephrol 26 7 2011 1083 1088
141. P. Niaudet, R. Habib Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis Pediatr Nephrol 12 3 1998 238 243
142. M. Zaffanello, M. Brugnara, M. Franchini Therapy for children with Henoch-Schönlein purpura nephritis: a systematic review ScientificWorldJournal 7 2007 20 30
143. J.M. Park, S.C. Won, J.I. Shin, H. Yim, K.S. Pai Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria Pediatr Nephrol 26 3 2011 411 417
144. J. Ronkainen, H. Autio-Harmainen, M. Nuutinen Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis Pediatr Nephrol 18 11 2003 1138 1142
145. O. Jauhola, J. Ronkainen, H. Autio-Harmainen Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial Pediatr Nephrol 26 12 2011 2159 2166
146. A.S. Bomback, G.B. Appel Updates on the treatment of lupus nephritis J Am Soc Nephrol 21 12 2010 2028 2035
147. B.H. Hahn, M.A. McMahon, A. Wilkinson American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Arthritis Care Res 64 6 2012 797 808
148. S. Duran-Barragan, G. McGwin Jr, L.M. Vila, J.D. Reveille, G.S. Alarcon Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus - results from LUMINA (LIX): a multiethnic US cohort Rheumatology 47 7 2008 1093 1096
149. G.K. Dube, G.S. Markowitz, J. Radhakrishnan, G.B. Appel, V.D. D'Agati Minimal change disease in systemic lupus erythematosus Clin Nephrol 57 2 2002 120 126
150. G. Contreras, D. Roth, V. Pardo, L.G. Striker, D.R. Schultz Lupus nephritis: a clinical review for practicing nephrologists Clin Nephrol 57 2 2002 95 107
151. F.A. Houssiau, C. Vasconcelos, D. D'Cruz Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum 46 8 2002 2121 2131
152. F.A. Houssiau, C. Vasconcelos, D. D'Cruz The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide Ann Rheum Dis 69 1 2011 61 64
153. Y. Lee, J.H. Woo, S. Choi, J. Ji, G. Song Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis Lupus 19 6 2010 703 710
154. B.H. Rovin, S.V. Parikh, L.A. Hebert Lupus nephritis: induction therapy in severe lupus nephritis - should MMF be considered the drug of choice? Clin J Am Soc Nephrol 8 1 2013 147 153
155. M. Walsh, N. Solomons, L. Lisk, D.R. Jayne Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management trial Am J Kidney Dis 61 5 2013 710 715
156. H. Bao, Z.H. Liu, H.L. Xie, W.X. Hu, H.T. Zhang, L.S. Li Successful treatment of class V+IV lupus nephritis with multitarget therapy J Am Soc Nephrol 19 10 2008 2001 2010
157. F.A. Houssiau, D. D'Cruz, S. Sangle Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial Ann Rheum Dis 69 12 2010 2083 2089
158. M.A. Dooley, D. Jayne, E.M. Ginzler Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis N Engl J Med 365 20 2011 1886 1895
159. J. Radhakrishnan, D.A. Moutzouris, E.M. Ginzler, N. Solomons, I.I. Siempos, G.B. Appel Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis Kidney Int 77 2 2010 152 160
160. E.M. Ginzler, M.A. Dooley, C. Aranow Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis N Engl J Med 353 21 2005 2219 2228
161. G.B. Appel, G. Contreras, M.A. Dooley Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis J Am Soc Nephrol 20 5 2009 1103 1112
162. A.S. Bomback, V.K. Derebail, J.G. McGregor, A.V. Kshirsagar, R.J. Falk, P.H. Nachman Rituximab therapy for membranous nephropathy: a systematic review Clin J Am Soc Nephrol 4 4 2009 734 744
163. G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli, P. Ruggenenti Rituximab for idiopathic membranous nephropathy Lancet 360 9337 2002 923 924
164. B.H. Rovin, R. Furie, K. Latinis Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment With Rituximab Study Arthritis Rheum 64 4 2012 1215 1226
165. B.J. Fessler, G.S. Alarcon, G. McGwin Jr Systemic lupus erythematosus in three ethnic groups: XVI Association of hydroxychloroquine use with reduced risk of damage accrual Arthritis Rheum 52 5 2005 1473 1480
166. No authors listed A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus The Canadian Hydroxychloroquine Study Group N Engl J Med 324 3 1991 150 154
167. G.J. Pons-Estel, G.S. Alarcon, G. McGwin Jr Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort 15 Arth Rheum 61 6 2009 830 839
168. J.S. Cheigh, K.H. Stenzel End-stage renal disease in systemic lupus erythematosus Am J Kidney Dis 21 1 1993 2 8
169. C. Ponticelli, G. Moroni Renal transplantation in lupus nephritis Lupus 14 1 2005 95 98
170. A. Howman, T.L. Chapman, M.M. Langdon Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial Lancet 381 9868 2013 744 751
171. M.E. Clowse, L. Magder, M. Petri Cyclophosphamide for lupus during pregnancy Lupus 14 8 2005 593 597
172. H. Kart Koseoglu, A.E. Yucel, G. Kunefeci, F.N. Ozdemir, H. Duran Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy Lupus 10 11 2001 818 820
173. G. Lannes, F.R. Elias, B. Cunha Successful pregnancy after cyclophosphamide therapy for lupus nephritis Arch Gynecol Obstet 283 suppl 1 2011 61 65
174. A.S. Fauci, B.F. Haynes, P. Katz, S.M. Wolff Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years Ann Intern Med 98 1 1983 76 85
175. A.S. Fauci, S.M. Wolff Wegener's granulomatosis: studies in eighteen patients and a review of the literature Medicine 52 6 1973 535 561
176. G.S. Hoffman, G.S. Kerr, R.Y. Leavitt Wegener granulomatosis: an analysis of 158 patients Ann Intern Med 116 6 1992 488 498
177. D. Jayne, N. Rasmussen, K. Andrassy A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies N Engl J Med 349 1 2003 36 44
178. K. de Groot, L. Harper, D.R. Jayne Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial Ann Intern Med 150 10 2009 670 680
179. L. Harper, M.D. Morgan, M. Walsh Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up Ann Rheum Dis 71 6 2012 955 960
180. R.B. Jones, J.W. Tervaert, T. Hauser Rituximab versus cyclophosphamide in
181. J.H. Stone, P.A. Merkel, R. Spiera Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med 363 3 2010 221 232
182. K. De Groot, N. Rasmussen, P.A. Bacon Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 52 8 2005 2461 2469
183. F. Silva, U. Specks, S. Kalra Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement - a prospective, open-label pilot trial Clin J Am Soc Nephrol 5 3 2010 445 453
184. D.R. Jayne, G. Gaskin, N. Rasmussen Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis J Am Soc Nephrol 18 7 2007 2180 2188
185. M. Walsh, F. Catapano, W. Szpirt Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis Am J Kidney Dis 57 4 2011 566 574
186. P.J. Klemmer, W. Chalermskulrat, M.S. Reif, S.L. Hogan, D.C. Henke, R.J. Falk Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis Am J Kidney Dis 42 6 2003 1149 1153
187. R. Cartin-Ceba, J.M. Golbin, K.A. Keogh Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center Arthritis Rheum 64 11 2012 3770 3778
188. C. Roubaud-Baudron, C. Pagnoux, N. Meaux-Ruault Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis J Rheumatol 39 1 2012 125 130
189. Stone JHM, Seo P, Spiera R, et al. for the RAVE-ITN Research Group. Rituximab Versus Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Trial (RAVE). Paper presented at: American College of Rheumatology Annual Scientific Meeting, November 2011; Philadelphia, PA.
190. C.A. Stegeman, J.W. Tervaert, P.E. de Jong, C.G. Kallenberg Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis Dutch Co-Trimoxazole Wegener Study Group N Engl J Med 335 1 1996 16 20
191. T.F. Hiemstra, M. Walsh, A. Mahr Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial JAMA 304 21 2010 2381 2388
192. C. Pagnoux, A. Mahr, M.A. Hamidou Azathioprine or methotrexate maintenance for ANCA-associated vasculitis N Engl J Med 359 26 2008 2790 2803
193. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis N Engl J Med 352 4 2005 351 361
194. D. Hollander, R.T. Manning The use of alkylating agents in the treatment of Wegener's granulomatosis Ann Intern Med 67 2 1967 393 398
195. M.C. Sneller, G.S. Hoffman, C. Talar-Williams, G.S. Kerr, C.W. Hallahan, A.S. Fauci An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone Arthritis Rheum 38 5 1995 608 613
196. V. Martinez, P. Cohen, C. Pagnoux Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients Arthritis Rheum 58 1 2008 308 317
197. M.M. Boomsma, C.A. Stegeman, M.J. van der Leij Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study Arthritis Rheum 43 9 2000 2025 2033
198. J.D. Finkielman, P.A. Merkel, D. Schroeder Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis Ann Intern Med 147 9 2007 611 619
199. J.R. Kerr, W.P. Ferguson, S.A. McMillan, I.N. Bruce, A.L. Bell Parvovirus B19 and acute joint swelling in rheumatoid arthritis patients Ann Rheum Dis 55 9 1996 648 649
200. J. Shen, J. Gill, M. Shangguan, M.S. Sampaio, S. Bunnapradist Outcomes of renal transplantation in recipients with Wegener's granulomatosis Clin Transplant 25 3 2011 380 387
201. G. Raman, A. Srivastava, D. Geetha Outcome of renal transplantation in patients with both ANCA and anti-GBM antibodies Transplantation 94 5 2012 e30 e31
202. J.P. Johnson, J. Moore Jr, H.A. Austin III, J.E. Balow, T.T. Antonovych, C.B. Wilson Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors Medicine 64 4 1985 219 227
203. D.R. Jayne, P.D. Marshall, S.J. Jones, C.M. Lockwood Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis Kidney Int 37 3 1990 965 970
204. J.B. Levy, T. Hammad, A. Coulthart, T. Dougan, C.D. Pusey Clinical features and outcome of patients with both ANCA and anti-GBM antibodies Kidney Int 66 4 2004 1535 1540
205. C.R. Hind, C. Bowman, C.G. Winearls, C.M. Lockwood Recurrence of circulating anti-glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange Clin Nephrol 21 4 1984 244 246
206. J.B. Levy, R.H. Lachmann, C.D. Pusey Recurrent Goodpasture's disease Am J Kidney Dis 27 4 1996 573 578